🔎 Trials Near Me

Beranda › Tumor Wilms › Tennessee

Uji klinis Tumor Wilms di Tennessee

6 studi untuk Tumor Wilms mencari peserta di lokasi di Tennessee.

Kota di Tennessee

Teks studi resmi (Bahasa Inggris)

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

  • Saint Jude Children's Research Hospital, Memphis
Menerima pesertaFase 2
Usia 12 hingga 39 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT04616560

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  • East Tennessee Childrens Hospital, Knoxville
  • Saint Jude Children's Research Hospital, Memphis
  • The Children's Hospital at TriStar Centennial, Nashville
  • dan 1 lainnya
Menerima pesertaFase 2
Hingga usia 30 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04322318

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Saint Jude Children's Research Hospital, Memphis
Menerima pesertaFase 1/2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04851119

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

  • St. Jude Children's Research Hospital, Memphis
Menerima pesertaFase 1
Hingga usia 21 · Semua jenis kelamin · Diperbarui 19 Mei 2026 · NCT04897321

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

  • St. Jude Children's Research Hospital, Memphis
Menerima pesertaFase 1/2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 19 Mei 2026 · NCT04901702

Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation

  • St.Jude Children's Research Hospital, Memphis
Menerima pesertaFase 2
Semua usia · Semua jenis kelamin · Diperbarui 23 Apr 2026 · NCT04968990

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.